News
CHMP recommends approval of Beovu for visual impairment in diabetic macular oedema.- Novartis
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Beovu (brolucizumab) from Novartis. The CHMP adopted a new indication for visual impairment in diabetic macular oedema.
The full indications for Beovu will therefore be as follows: Beovu is indicated in adults for the treatment of neovascular (wet) age related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME).
Condition: Diabetic Macular Oedema
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.